Nicardipine Pediatric Dose — Cardiovascular Infusions
Nicardipine is a second-generation dihydropyridine calcium channel blocker that reduces systemic vascular resistance through selective arterial smooth muscle relaxation. In pediatrics, it is used primarily for the management of hypertensive urgency and emergency requiring titratable, continuous intravenous antihypertensive therapy. Its predictable dose-response profile and short half-life make it a practical option in the PICU setting.
Pediatric Dosing
Nicardipine is administered as a continuous IV infusion at 0.25–5 mcg/kg/min. Initiate at the lower end of the range and titrate to the desired blood pressure response.
- Starting dose: 0.25 mcg/kg/min IV infusion
- Maximum dose: 5 mcg/kg/min IV infusion
Titrate gradually based on hemodynamic response and patient tolerance. Consult institutional protocol for specific titration intervals and target blood pressure goals.
Worked example: For a 20 kg child, the starting infusion rate would be 20 × 0.25 mcg/kg/min = 5 mcg/min, and the maximum rate would be 20 × 5 mcg/kg/min = 100 mcg/min.
Indications and Clinical Context
Nicardipine is indicated for pediatric hypertensive emergencies requiring rapid, controlled blood pressure reduction with continuous titration. Common clinical scenarios include hypertensive encephalopathy, acute glomerulonephritis, and perioperative hypertension. Its arterial selectivity with minimal negative inotropy makes it preferable in patients where cardiac output must be preserved.
As a titratable IV antihypertensive agent, nicardipine aligns with recommended approaches for acute severe hypertension in children per standard critical care guidelines. It offers the advantage of a relatively short duration of action, allowing prompt dose adjustment in response to clinical changes.
Administration and Monitoring
Central venous line (CVL) administration is preferred to reduce the volume of fluid administered and to minimize the risk of peripheral vein irritation, as nicardipine solutions are associated with phlebitis when given peripherally over extended periods. Peripheral administration may be considered short-term if CVL access is unavailable, per institutional protocol.
- Administer as a continuous IV infusion only; do not give as an IV bolus.
- Monitor blood pressure continuously or at frequent intervals during titration.
- Adverse effects to monitor include hypotension, reflex tachycardia, headache, and peripheral edema.
- Use with caution in patients with advanced aortic stenosis.
- Consult institutional protocol for maximum concentration, compatible diluents, and titration intervals.
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.